Report Highlights
The global market for radioligand therapeutics in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.1% from 2025 through 2030.
Report Includes
- 15 data tables and 57 additional tables
- Overview and an analysis of the global markets for radioligand therapeutics (RLT) in cancer treatment
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on product type, disease indication, end user and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
- Highlights of promising new advancements in precision oncology, the emergence of innovative and effective theranostic agents, applications and potential
- Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Novartis AG, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Ltd., RayzeBio Inc., and Lilly USA LLC.
Report Scope
This report provides an in-depth analysis of the global market for radioligand therapeutics (RLT) in cancer treatment. It presents detailed market data for 2024 (base year), estimates for 2025 and forecasts with compound annual growth rates (CAGR) through 2030. The study evaluates current market dynamics, emerging trends and future growth potential driven by the adoption of prostate-specific membrane antigen (PSMA)- and somatostatin receptor (SSTR)-targeted therapies.
The report assesses the competitive environment, including product-level analysis of approved radioligand therapies such as 177Lu-vipivotide tetraxetan (Pluvicto) and 177Lu-dotatate (Lutathera), as well as pipeline assets targeting PSMA, SSTR, gastrin‐releasing peptide receptor (GRPR) and other tumor-specific receptors. It also examines regulatory pathways and reimbursement frameworks.
Market segmentation encompasses product type, indication type, and end user, with additional assessments of drivers, restraints, opportunities, technological advances, and strategic activities such as collaborations, acquisitions, clinical trial investments, and expansion of isotope production capacity.
Segmental-level market data (by product type, indication type and end user) is limited to the North America region. This limitation highlights that the market for radioligand therapeutics in cancer treatment is centered in the U.S., where a single company’s products (Pluvicto and Lutathera from Novartis AG) account for the majority of global sales and where reliable, detailed data are accessible. In other regions, RLT is still in an early stage, with limited commercial adoption and insufficient transparent data to enable detailed segment-level analysis.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2024 | ||||||||||||||||
| Forecast period considered | 2025-2030 | ||||||||||||||||
| Base year market size | $2.1 Billion | ||||||||||||||||
| Market size forecast | $4.8 Billion | ||||||||||||||||
| Growth rate | CAGR of 13.1% from 2025 to 2030 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | By Product Type, Disease Indication, End User, and Region | ||||||||||||||||
| Regions covered | North America, Europe and the Emerging Markets | ||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||
| Companies studied |
|
||||||||||||||||
Frequently Asked Questions (FAQs)
- Rising cancer incidence and a growing aging population.
- Increasing approvals and label expansions of radioligand therapeutics products.
- CMS separate payment for therapeutic radiopharmaceuticals.
- Therapeutic isotope supply constraints.
- Nuclear medicine and radiopharmacy workforce shortages.
- Growing competition from alternative modalities, such as ADCs.
- Advancement of alpha-emitter therapies and novel targets.
- Earlier-line use and combination regimens with standard of care.
- Increasing R&D investments and strategic alliances.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Related Reports
Pharmaceutical Filtration: Global Markets
The global market for pharmaceutical filtration is expected to grow from $12 billion in 2025 and is projected to reach $20.3 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.1% during the forecast period of 2025 to 2030.
Bioprocess Optimization and Digital Bio-manufacturing: Global Markets
The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Sterile Filtration Market for Lifescience
The global sterile filtration market should reach $5.3 billion by 2027 from $3.0 billion in 2022 at a compound annual growth rate (CAGR) of 12.0% for the forecast period of 2022 to 2027.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Neuroprotective Agents: Therapeutic Applications and Global Markets
The global market for neuroprotective agents is expected to grow from $43.9 billion in 2025 and is projected to reach $60.9 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.7% during the forecast period of 2025 to 2030.
Radioligand Therapeutics in Cancer Treatment: Global Markets
The global market for radioligand therapeutics in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.1% from 2025 through 2030.
Monoclonal Antibodies for Oncology: Global Markets
The global market for monoclonal antibodies in oncology is expected to grow from $129.3 billion in 2025 and is projected to reach $228 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12% during the forecast period of 2025 to 2030.
Cannabis Market: Products, Technologies, and Applications
The global market for cannabis was valued at $45.6 billion in 2025 and is projected to reach $79.3 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.7% during the forecast period of 2025 to 2030.
Global Oncology Biosimilars Market
The global market for oncology biosimilars is estimated to grow from $9.6 billion in 2025 and projected to reach $17.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2030.
Top Trending Reports
Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing
The global market for genetic modification therapies is estimated to grow from $14.8 billion in 2025 to reach $32.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.8% from 2025 through 2030.
State of the Life Sciences Industry - Fourth Quarter Review
State of the Life Sciences Industry Market Report delivers insights on biotech, pharma, medical devices, innovation trends, and global market outlook.
Carbon Fiber: Global Markets
The global market for carbon fiber was valued at $4.9 billion in 2024 and is estimated to increase from $5.3 billion in 2025 to reach $8.2 billion by 2030, at a compound annual growth rate (CAGR) of 9.1% from 2025 through 2030.
Global Markets for Diabetes Therapeutics and Diagnostics
The global market for diabetes therapeutics and diagnostics is estimated to grow from $134.9 billion in 2025 to reach $241.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% from 2025 through 2030.
Sleep Aids: Technologies and Global Markets
The global market for sleep aid technologies is estimated to grow from $103.5 billion in 2025 to reach $136 billion by 2030, at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2030.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More